癌症研究
硫氧化物9
小RNA
神经发生
心理压抑
干细胞
下调和上调
胶质瘤
胶质母细胞瘤
表型
激酶
生物
细胞生物学
神经科学
基因表达
基因
遗传学
作者
Hanna Sabelström,Rebecca Petri,Ksenya Shchors,Rahul Jandial,Christin Schmidt,Rohit Sacheva,Selma Masic,Edith Yuan,Trenten Fenster,Michael Martinez,Supna Saxena,Theodore Nicolaides,Shirin Ilkhanizadeh,Mitchel S. Berger,Evan Y. Snyder,William A. Weiss,Johan Jakobsson,Anders I. Persson
出处
期刊:Cell Reports
[Elsevier]
日期:2019-08-01
卷期号:28 (8): 2064-2079.e11
被引量:40
标识
DOI:10.1016/j.celrep.2019.07.071
摘要
Identifying cellular programs that drive cancers to be stem-like and treatment resistant is critical to improving outcomes in patients. Here, we demonstrate that constitutive extracellular signal-regulated kinase 1/2 (ERK1/2) activation sustains a stem-like state in glioblastoma (GBM), the most common primary malignant brain tumor. Pharmacological inhibition of ERK1/2 activation restores neurogenesis during murine astrocytoma formation, inducing neuronal differentiation in tumorspheres. Constitutive ERK1/2 activation globally regulates miRNA expression in murine and human GBMs, while neuronal differentiation of GBM tumorspheres following the inhibition of ERK1/2 activation requires the functional expression of miR-124 and the depletion of its target gene SOX9. Overexpression of miR124 depletes SOX9 in vivo and promotes a stem-like-to-neuronal transition, with reduced tumorigenicity and increased radiation sensitivity. Providing a rationale for reports demonstrating miR-124-induced abrogation of GBM aggressiveness, we conclude that reversal of an ERK1/2-miR-124-SOX9 axis induces a neuronal phenotype and that enforcing neuronal differentiation represents a therapeutic strategy to improve outcomes in GBM.
科研通智能强力驱动
Strongly Powered by AbleSci AI